MacroGenics, Inc. MGNX
3.74
(0.06)
(1.58%)
as of 25 Sep
- Market cap
- $242.1M
- P/E
- 0.0×
Follow MGNX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.61 | 1.17 | 0.68 | 0.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.21) | (5.12) | 2.36 | (3.52) | |
P/B ratio |
6.85 | 8.65 | 1.83 | 1.59 | |
Price to Tangible BV |
6.85 | 8.65 | 1.83 | 1.59 | |
EV/Sales |
0.69 | 0.23 | (0.55) | (0.30) | |
EV/EBITDA |
0.00 | 0.00 | 1.22 | 0.30 | |
EV/Operating CF |
(1.99) | (0.51) | 1.01 | 0.21 | |
EV/FCF |
(1.94) | (0.50) | 0.99 | 0.21 | |
Quick Ratio |
2.92 | 1.72 | 4.41 | 4.85 | |
Current Ratio |
2.96 | 1.90 | 5.10 | 5.22 | |
Net Debt/EBITDA |
12.75 | 4.75 | 41.57 | (7.35) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.62 | 0.71 | 0.58 | 0.42 | |
Operating CF/Net income |
(2.09) | 0.97 | (3.04) | (1.79) | |
Capex/Depreciation |
(3.06) | (0.36) | (0.22) | (0.33) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
118.12% | 168.35% | 60.02% | 44.91% | |
Selling, General and Administrative Expense of Revenue |
24.07% | 46.74% | 16.32% | 13.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.01% | 12.74% | 4.70% | 4.87% | |
Graham Net Nets |
0.07 | (0.08) | 0.18 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.76%) | (38.06%) | (72.67%) | (71.43%) | |
Free Cash Flow Yield |
(22.30%) | (39.09%) | (81.57%) | (155.09%) | |
Revenue per Share |
0.52 | 0.33 | 0.90 | 1.15 | |
Operating CF per Share |
(0.64) | (0.56) | 0.68 | (0.48) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.65) | (0.57) | 0.68 | (0.48) | |
Cash per Share |
2.73 | 2.43 | 3.01 | 2.32 | |
Shareholders Equity per Share |
0.67 | 0.33 | 0.88 | 1.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.67 | 0.33 | 0.88 | 1.06 | |
Free Cash Flow |
(41.55) | (36.15) | 42.79 | (30.61) | |
Working Capital |
212.87 | 86.58 | 176.83 | 187.62 | |
Capital Expenditures |
(0.81) | (0.34) | (0.23) | (0.43) | |
Net Current Asset Value |
19.15 | (14.15) | 18.69 | 28.33 | |
EV/EBIT |
0.00 | 0.00 | 1.12 | 0.28 | |
Capex to Sales |
0.02 | 0.02 | 0.00 | 0.01 | |
Net Profit Margin |
59.44% | (177.01%) | (25.01%) | 23.09% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
78.35 | 10.48 | 2.37 | 38.99 | |
Average Payables |
4.05 | 5.45 | 4.14 | 6.28 | |
Average Inventory |
— | 9.46 | 5.58 | 4.93 | |
Average Assets |
295.41 | 221.22 | 259.25 | 267.63 | |
Average Common Equity |
44.75 | 50.16 | 85.82 | 93.53 |
Columns are period end dates